Hainan's tax incentives have created a favorable development environment for medical firms, helping them reduce costs and increase R&D capabilities, thus promoting their robust growth. Take Susheng Biotech (Hainan) as an example, its founder Zeng Sheng said that the company is booming in Hainan. The specific manifestations are as follows:Significant cost savings: Hainan has a 15% corporate and personal income tax rate for eligible businesses and high - end talent. This enables Susheng Biotech to reduce management costs by about 15% compared with competitors on the Chinese mainland. In addition, for medical innovation enterprises like Susheng Biotech, which mainly rely on imported equipment, Hainan's "zero - tariff" policy on imported medical equipment and materials for medical implants has saved the company about 20% in production costs.Easy access to preferential policies: Hainan has an "ultra - simple approval" system, with minimal approval requirements for items subject to evaluation and examination. This allows medical firms to access advanced global medicines with streamlined approvals. At the same time, the company has also obtained a 6 - million - yuan bank loan without collateral, which is conducive to the company's capital turnover and business expansion.In addition to Susheng Biotech, many other medical firms in Hainan have also benefited from tax incentives. For example, Qilu Pharmaceutical (Hainan) Co., Ltd. has enjoyed the dividends brought by the "zero - tariff" policy on self - used production equipment and duty - free processing and value - added. Hainan Pulice Pharmaceutical Co., Ltd. has enjoyed a number of policies such as "zero - tariff on self - used equipment" and "tax exemption for raw and auxiliary materials on the positive list", which has brought it broader international trade cooperation opportunities.
|
|